The Wainwright analyst I was talking about was Patrick R. Trucchio. And I didn't see VIR get above the $80 range. That seems to happen, when products aren't variant agnostic.
So there is still a significant unmet need that lenz could fill, if the NIH/NIAID and the FDA can't figure out a way to keep us from penetrating the US market.